Theravance Biopharma (TBPH) Misses Q1 EPS by 14c

Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($1.10), $0.14 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $18.4 million versus the consensus estimate of $18.69 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Abercrombie & Fitch (ANF) Tops Q2 EPS by $2.19, Offers Guidance
• Gulf Resources signs cooperation deal with Brazilian mining firm
• Zhihu Inc. (ZH) Reports Q2 Revenue Below Estimates